Autism spectrum disorder-associated biomarkers for case evaluation and management by clinical geneticists

References

• Austin D. An epidemiological analysis of the ‘autism as mercury poisoning’ hypothesis. Int. J. Risk Saf. Med.20(3), 135–142 (2008).
   Google Scholar
• White JF. Intestinal pathophysiology in autism. Exp. Biol. Med. (Maywood)228(6), 639–649 (2003).
   PubMed Web of Science ®Google Scholar
• Sweeten TL, Bowyer SL, Posey DJ et al. Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics112(5), e420 (2003).
   Web of Science ®Google Scholar
• Bolte S, Poustka F. The relation between general cognitive level and adaptive behavior domains in individuals with autism with and without co-morbid mental retardation. Child Psychiat. Hum. Dev.33(2), 165–172 (2002).
   PubMed Web of Science ®Google Scholar
• Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders – autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMWR. Surveill. Summ.56(1), 12–28 (2007).
   PubMedGoogle Scholar
• Schaefer GB, Mendelsohn NJ. The Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders. Genet. Med.10(4), 301–305 (2008).
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. A prospective study of mercury toxicity biomarkers in autistic spectrum disorders. J. Toxicol. Environ. Health A70(20), 1723–1730 (2007).
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. A prospective assessment of porphyrins in autistic disorders: a potential marker for heavy metal exposure. Neurotox. Res.10(1), 57–64 (2006).
   PubMed Web of Science ®Google Scholar
• Nataf R, Skorupka C, Amet L, Lam A, Springbett A, Lathe R. Porphyrinuria in childhood autistic disorder: implications for environmental toxicity. Toxicol. Appl. Pharmacol.214(2), 99–108 (2006).
   PubMed Web of Science ®Google Scholar
• Nataf R, Skorupka C, Lam A, Springbett A, Lathe R. Porphyrinuria in childhood autistic disorder is not associated with urinary creatinine deficiency. Pediatr. Int.50(2), 528–532 (2008).
   PubMed Web of Science ®Google Scholar
• Austin DW, Shandley K. An investigation of porphyrinuria in Australian children with autism J. Toxicol. Environ. Health A71(20), 1349–1351 (2008).
   PubMed Web of Science ®Google Scholar
• Geier DA, Kern JK, Garver CR et al. Biomarkers of environmental toxicity and susceptibility in autism. J. Neurol. Sci. DOI:10.1016/j.jns.2008.08.021 (2008) (Epub ahead of print).
   Google Scholar
• Sajdel-Sulkowska EM, Lipinski B, Windom H, Audhya T, McGinnis W. Oxidative stress in autism: elevated cerebellar 3-nitrotyrosine levels. Am. J. Biochem. Biotechnol.4(2), 73–84 (2008).
   Google Scholar
• Desoto MC, Hitlan RT. Blood levels of mercury are related to diagnosis of autism: a reanalysis of an important data set. J. Child. Neurol.22(11), 1308–1311 (2007).
   PubMed Web of Science ®Google Scholar
• Adams JB, Romdalvik J, Ramanujam VM, Legator MS. Mercury, lead, and zinc in baby teeth of children with autism versus controls. J. Toxicol. Environ. Health A70(12), 1046–1051 (2007).
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders. J. Toxicol. Environ. Health A70(10), 837–851 (2007).
   PubMed Web of Science ®Google Scholar
• Adams JB, Romdalvik J, Levine KE, Hu LW. Mercury in first-cut baby hair of children with autism versus typically developing children. Toxicol. Environ. Chem. DOI:10.1080/02772240701699294 (2008) (In Press).
   PubMedGoogle Scholar
• Domingo JL. Prevention by chelating agents of metal-induced developmental toxicity. Reprod. Toxicol.9(2), 105–113 (1995).
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders. Neuro. Endocrinol. Lett. (6), 833–838 (2006).
   PubMed Web of Science ®Google Scholar
• Kern JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J. Toxicol. Environ. Health B Crit. Rev.9(6), 485–499 (2006).
   PubMed Web of Science ®Google Scholar
• Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur. J. Pediatr.157(Suppl. 2), S40–S44 (1998).
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders. Horm. Res.66(4), 182–188 (2006).
   PubMed Web of Science ®Google Scholar
• Geier DA, Kern JK, Garver CR, Adams JB, Audhya T, Geier MR. A prospective study of transsulfuration biomarkers in autistic disorders. Neurochem. Res. DOI:10.1007/s11064-008-9782-x (2008) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• James SJ, Melnyk S, Jernigan S et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am. J. Med. Genet. B Neuropsychiatr. Genet.141B(8), 947–956 (2006).
   PubMed Web of Science ®Google Scholar
• James SJ, Cutler P, Melnyk S et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am. J. Clin. Nutr.80(6), 1611–1617 (2004).
   PubMed Web of Science ®Google Scholar
• Pasca SP, Dronca E, Kaucsár T et al. One carbon metabolism disturbances and the C677T MTHFR gene polymorphism in children with autism spectrum disorders. J. Cell. Mol. Med. DOI: 10.1111/j.1582-4934. 2008. 00463.x (2008) (In Press).
   Google Scholar
• Mousain-Bosc M, Roche M, Polge A, Pradal-Prat D, Rapin J, Bali JP. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. Magnes. Res.19(1), 53–62 (2006).
   PubMed Web of Science ®Google Scholar
• Yorbik O, Sayal A, Akay C, Akbiyik DI, Sohmen T. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot. Essent. Fatty Acids67(5), 341–343 (2002).
   PubMed Web of Science ®Google Scholar
• Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin--the antioxidant proteins. Life Sci.75(21), 2539–2549 (2004).
   PubMed Web of Science ®Google Scholar
• Zoroglu SS, Armutcu F, Ozen S et al. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur. Arch. Psychiatry Clin. Neurosci.254(3), 143–147 (2004).
   PubMed Web of Science ®Google Scholar
• Sogut S, Zoroglu SS, Ozyurt H et al. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin. Chim. Acta331(1–2), 111–117 (2003).
   PubMed Web of Science ®Google Scholar
• Boso M, Emanuele E, Minoretti P et al. Alternations of circulating endogenous secretory RAGE and S100A9 levels indicating dysfunction of the AGE–RAGE axis in autism. Neurosci. Lett.410(3), 169–173 (2006).
   PubMed Web of Science ®Google Scholar
• Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann. Neurol.57(1), 67–81 (2005).
   PubMed Web of Science ®Google Scholar
• Bradstreet JJ, Smith S, Granpeesheh D, El-Dahr JM, Rossignol D. Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders. Med. Hypotheses68(5), 979–987 (2007).
   PubMed Web of Science ®Google Scholar
• Baron-Cohen S, Knickmeyer RC, Belmonte MK. Sex differences in the brain: implications for explaining autism. Science310(5749), 819–823 (2005).
   PubMed Web of Science ®Google Scholar
• Knickmeyer R, Baron-Cohen S, Fane BA et al. Androgens and autistic traits: a study of individuals with congenital adrenal hyperplasia. Horm. Behav.50(1), 148–153 (2006).
   PubMed Web of Science ®Google Scholar
• Knickmeyer RC, Wheelwright S, Hoekstra R, Baron-Cohen S. Age of menarche in females with autism spectrum conditions. Dev. Med. Child. Neurol.48(12), 1007–1008 (2006).
   PubMed Web of Science ®Google Scholar
• Ingudomnukul E, Baron-Cohen S, Wheelwright S, Knickmeyer R. Elevated rates of testosterone-related disorders in women with autism spectrum conditions. Horm. Behav.51(5), 597–604 (2007).
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. A prospective assessment of androgen levels in patients with autistic spectrum disorders: biochemical underpinnings and suggested therapies. Neuro. Endocrinol. Lett.28(5), 565–573 (2007).
   PubMed Web of Science ®Google Scholar
• Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deficiency in autism. J. Autism Dev. Disorder34(6), 615–623 (2004).
   PubMed Web of Science ®Google Scholar
• Poling JS, Frye RE, Shoffner J, Zimmerman AW. Developmental regression and mitochondrial dysfunction in a child with autism. J. Child Neurol.21(2), 170–172 (2006).
   PubMed Web of Science ®Google Scholar
• Oliveira G, Diogo L, Grazina M et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev. Med. Child Neurol.47(3), 185–189 (2005).
   PubMed Web of Science ®Google Scholar
• Boris M, Goldblatt A, Galanko J, James SJ. Association of MTHFR gene variants with autism. J. Am. Phys. Surg.9(4), 106–108 (2004).
   Google Scholar